Oct 23 (Reuters) - Sumitovant Biopharma Ltd, along with parent Sumitomo Pharma Co Ltd, has entered into a deal to purchase all shares of Myovant Sciences not already owned by Sumitovant for $27 per share, the companies said in a statement on Sunday. (Reporting by Ann Maria Shibu in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
363 JPY | +0.83% | -9.02% | -22.10% |
05-07 | Profit-Taking, China Outlooks Churn Asian Stock Markets | MT |
05-02 | Fed Outlook, Earnings Season Roil Asian Stock Markets | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.10% | 926M | |
+33.02% | 700B | |
-4.82% | 358B | |
+19.01% | 330B | |
+3.47% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.22% | 161B | |
-2.14% | 157B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitovant Biopharma to buy Myovant for $27 per share